CCL19 and triple-negative breast carcinoma: Notably, immunotherapy-treated patients had a higher proportion of mature TLSs compared to untreated patients (50.7% vs. 41.3%).152 Data from a study involving patients with triple-negative breast cancer suggests that TME with high levels of CCL19+ DC infiltration is characterized by immunogenic structures.